Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Sep 2025 value amounting to $269,000.

  • Orchestra BioMed Holdings' Gains from Investment Securities fell 60.21% to $269,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 36.79%. This contributed to the annual value of $1.2 million for FY2024, which is 308.84% up from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Gains from Investment Securities stood at $269,000 for Q3 2025, which was down 37.15% from $428,000 recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Gains from Investment Securities registered a high of $1.0 million during Q2 2022, and its lowest value of -$36,000 during Q3 2022.
  • Its 3-year average for Gains from Investment Securities is $368,571, with a median of $387,000 in 2025.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 103.74% in 2024, then spiked by 3,618.18% in 2025.
  • Quarterly analysis of 4 years shows Orchestra BioMed Holdings' Gains from Investment Securities stood at $226,000 in 2022, then skyrocketed by 102.76% to $294,000 in 2023, then slumped by 103.74% to $537,000 in 2024, then plummeted by 60.21% to $269,000 in 2025.
  • Its Gains from Investment Securities stands at $269,000 for Q3 2025, versus $428,000 for Q2 2025 and $387,000 for Q1 2025.